Adial Pharmaceuticals logo
Adial Pharmaceuticals ADIL
$ 1.6 0.0%

Annual report 2025
added 03-05-2026

report update icon

Adial Pharmaceuticals Net Debt 2011-2026 | ADIL

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Adial Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - -5.85 M -4.4 M -6.78 M -3.87 M 671 K 146 K -162 K - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
671 K -6.78 M -2.89 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
BioNTech SE BioNTech SE
BNTX
-973 M $ 95.5 -3.88 % $ 27.2 B germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
2.27 M - 2.54 % $ 160 B franceFrance
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
-68.5 M - - $ 269 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
-12.1 M - - $ 231 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
-83 M $ 22.35 0.72 % $ 3.7 B usaUSA
Galapagos NV Galapagos NV
GLPG
-1.29 B $ 28.39 -0.13 % $ 2.69 B belgiumBelgium
Grifols, S.A. Grifols, S.A.
GRFS
5.36 B $ 8.27 0.49 % $ 6.83 B spainSpain
Advaxis Advaxis
ADXS
3.42 M - -9.65 % $ 45.9 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-3.5 M $ 3.5 5.42 % $ 5.76 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-31.2 M - 1.93 % $ 17.4 M usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
-32.3 M $ 1.97 -7.51 % $ 152 M germanyGermany
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
-5.53 M - -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
-33.8 M - -39.0 % $ 4.57 M usaUSA
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
-239 M - -0.23 % $ 916 M usaUSA
Allakos Allakos
ALLK
-25 M - - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
-62.7 M - 4.14 % $ 49.1 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
65.3 M $ 23.42 -0.3 % $ 2.98 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-29.5 M - 3.16 % $ 1.9 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-12 M - -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-56.5 M - - $ 10.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-63.9 M - - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.44 M - 10.36 % $ 9.8 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
-49.4 M - - $ 8.42 M usaUSA
Aravive Aravive
ARAV
-49.6 M - -13.39 % $ 1.45 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
-3.05 M - 17.91 % $ 11.1 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
-120 M $ 1.4 -2.1 % $ 235 M franceFrance
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
-141 M $ 52.38 -2.24 % $ 4.71 B schweizSchweiz
Avenue Therapeutics Avenue Therapeutics
ATXI
-3.13 K - -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-32.7 M $ 1.64 4.46 % $ 436 M britainBritain
Inventiva S.A. Inventiva S.A.
IVA
-95.6 M $ 5.42 2.85 % $ 138 M franceFrance
AVROBIO AVROBIO
AVRO
-76.6 M - 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-657 K - - $ 7.46 M israelIsrael
Завод ДИОД Завод ДИОД
DIOD
-48.6 M - - - russiaRussia
Фармсинтез Фармсинтез
LIFE
612 M - - - russiaRussia
AstraZeneca PLC AstraZeneca PLC
AZN
9.86 B - - $ 96.9 B britainBritain
Atreca Atreca
BCEL
33.1 M - -11.76 % $ 5.79 M usaUSA